as 03-28-2025 4:00pm EST
Founded: | 1993 | Country: | United States |
Employees: | N/A | City: | NEW YORK |
Market Cap: | N/A | IPO Year: | 1995 |
Target Price: | $40.67 | AVG Volume (30 days): | 3.5M |
Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.15 | EPS Growth: | 68.03 |
52 Week Low/High: | $12.93 - $43.32 | Next Earning Date: | 03-03-2025 |
Revenue: | $329,004,000 | Revenue Growth: | 40.80% |
Revenue Growth (this year): | 73.72% | Revenue Growth (next year): | 38.19% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Power Sean A | TGTX | CFO | Jan 3 '25 | Sell | $29.41 | 21,358 | $629,382.29 | 670,632 |
TGTX Breaking Stock News: Dive into TGTX Ticker-Specific Updates for Smart Investing
Argus Research
4 days ago
Investor's Business Daily
8 days ago
Insider Monkey
10 days ago
Zacks
12 days ago
Insider Monkey
15 days ago
Investor's Business Daily
18 days ago
Simply Wall St.
20 days ago
Investor's Business Daily
21 days ago
The information presented on this page, "TGTX TG Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.